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diagnosis. Prevalence comparisons were calculated using z-scores
of log odds ratios (Woolf method), and the average cost (for the
entire cohort) comparisons were calculated using Sattherthwaite
t-tests. RESULTS: A total of 12,308 employees with insomnia
and 36,924 matched controls were analyzed. Results are pre-
sented for each comorbid condition as: (% insomnia prevalence:
% control prevalence, insomnia costs: control costs). Mental
Disorders: Dissociative/Personality Disorders (15.88%:3.32%,
$34:$6); Affective Disorders (14.54%:2.92%, $125:$17);
Substance-Related Mental Disorders (2.00%:0.80%, $7:$1);
Alcohol-Related Mental Disorders (0.89%:0.22%, $18:$3);
Other Mental Conditions (15.17%:4.27%, $44:$11); Other
Psychoses (0.24%:0.05%, $2:$0). Respiratory System: As-
thma (6.24%:3.04%, $20:$8); COPD and Bronchiectasis
(4.14%:2.23%, $10:$5). Nervous System Sense Organs: Head-
ache including Migraine (13.07%:5.16%, $54:$16); Dizziness/
Vertigo (4.95%:2.35%, $16:$8); Hereditary/Degenerative
Nervous System Condition (1.09%:0.22%, $5:$1); Other
Nervous System Disorders (34.20%:5.01%, $168:$40). Injury/
Poisoning: Sprains and Strains (13.40%:7.52%, $69:$31);
Fracture-Lower Limb (1.58%:0.95%, $26:$8); Fracture-Upper
Limb (1.26%:0.71%, $15:$7). Other Conditions: Rheumatoid
Arthritis (1.31%:0.52%, $19:$7); Malaise and Fatigue
(15.20%:5.81%, $14:$5); Syncope (1.59%:0.72%, $14:$5);
Chronic Renal Failure (0.50%:0.13%, $74:$7); Breast Cancer
(1.20%:0.67%, $112:$26). Overall, employees in the insomnia
cohort had signiﬁcantly higher prevalence (80.8%) and costs
(47.5%) for the 261 conditions compared with the matched
controls (p < 0.05). CONCLUSION: Employees with insomnia
have more prevalent comorbid conditions than subjects without
insomnia. From an insurer’s perspective, this increased burden
for insomnia sufferers is also associated with higher costs.
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OBJECTIVES: To analyse hospital outpatient treatment patterns
and costs associated with Restless Legs Syndrome (RLS) in Italy
before the non-ergot derived dopamine agonist pramipexole was
approved in the treatment of RLS. RLS is a common, although
largely under-diagnosed, neurological disorder producing nega-
tive effects on patients’ quality of life. METHODS: A retrospec-
tive database analysis was conducted using the database of the
Sleep Disorders Centre of San Raffaele Hospital in Milan. The
database records each patient’s sleep disorder, baseline charac-
teristics, drug prescriptions and medical procedures. 2,000
patients included in the database were screened in order to iden-
tify patients affected by RLS symptoms and to calculate resource
use associated with the treatment of RLS from January 2004 to
March 2005. RESULTS: In total, 122 patients (6% of all patients
in the database) were diagnosed with RLS symptoms and conse-
quently included in the study: mean age was found to be 52 years
and 68% were women. All patients received at least three differ-
ent drug classes over the observation period. The most frequently
prescribed treatments were: benzodiazepines (64%), antidepres-
sants (23%) anticonvulsants (4%), NSAIDS (4%) and oxerutines
(5%). The total average cost per patient per year was € 289.09,
including drug costs (€ 242.79), diagnostic tests (€ 32.67) and
physician visits (€ 13.63). CONCLUSION: This was the ﬁrst
effort to evaluate hospital outpatient treatment patterns and
costs for RLS in Italy. The majority of the annual treatment costs
incurred by RLS patients were associated with currently unli-
censed treatment options which can place an additional cost
burden on the public health care system while treatment out-
comes are limited.
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OBJECTIVES: To analyze longitudinal health and non-health
resources utilization (HRU) and derived costs of treating refrac-
tory pain due to Trigeminal Neuralgia in Primary Care Setting
(PCS) during 12-weeks under routine medical practice.
METHODS: Sub-analysis of patients above 18 years, with
chronic pain (6-month or more) due to trigeminal neuralgia
refractory to, at least, one previous analgesic [previous mean
(SD) number of drugs was 2.2 (1.2), with a 36.3% on one-
drug only], included in a prospective, naturalistic, 12-weeks
two-visit study on refractory peripheral Neuropathic pain.
Health resources included all-type medical visits, hospitaliza-
tions, complementary test and pharmacological and non-
pharmacological therapies. Non-health included wages loses due
to loss-work-days equivalents (LWDE = absenteeism days + days
working with reduced productivity due to pain). Pain severity
was measured by McGill-pain scale. Descriptive statistics and
paired-t and non-parametric tests were applied. RESULTS:
Ninety-one [62.2% women, 57.7 (13.9) years] patients were
analyzed: 45% switched to pregabalin as a monotherapy, 37%
received pregabalin as add-on therapy, and in 18% previous
treatment was replaced by a regimen not including pregabalin.
Signiﬁcant reduction in last-week mean pain severity [-35.0
(23.9) mm, p < 0.0001] was accompanied by reductions in quar-
terly mean LWDE of -23.7 (23.6) days, p < 0.0001, average total
medical visits per trimester of -5.4 (7.6) visits, p < 0.0001 and
percentage of most subjects-prescribed complementary test.
The extra costs of drugs, due to pregabalin [+€133.5 (115.2),
p < 0.0001], was off-set by higher signiﬁcant reductions in all
other components of health costs yielding to a greater total,
direct and indirect costs reductions: €-1646.2 (1638.6), €-549.6
(1131.8) and €-1096.6 (1173.1), respectively (p < 0.0001 in all
cases). CONCLUSION: A therapy mix of painful trigeminal
neuralgia mostly based on pregabalin (82% of cases) was asso-
ciated with a signiﬁcant longitudinal reduction in health
resources utilization and total costs in the primary care setting
under routine medical practice.
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OBJECTIVES: Multiple sclerosis (MS) is a chronic progressive
irreversible neurological disease. Individuals often experience a
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